IgLON5 autoimmunity secondary to immune checkpoint inhibitor.

IgLON5 autoimmunity is characterized by a diverse range of clinical presentations, including neuropsychiatric symptoms, sleep disturbances, gait instability, and bulbar symptoms, that are usually insidiously progressive. While some individuals with specific HLA haplotypes may be more susceptible to developing anti-IgLON5 disease, this antibody is typically not associated with a paraneoplastic etiology nor known to be induced by immune checkpoint inhibitors (ICI). We present a clinical and serological workup of a patient who developed symptoms of IgLON5 autoimmunity following treatment with pembrolizumab.

Introduction of substituents for tuning the redox properties of benzoate-bridged paddlewheel diruthenium(II,II) complexes: what does the OH group bring?

Benzoate-bridged paddlewheel diruthenium(II,II) complexes ([RuII,II2(RArCO)(L)] (L = axial ligand); [RuII,II2]) exhibit reversible redox activity involving the oxidized species [RuII,III2]. The redox activity can be finely tuned over a broad potential range by altering the substituent R on the benzoate-bridging ligand RArCO. The electronic contributions of the substituents R depend on their type and position, as was empirically demonstrated by Hammett for substituents at the - and -positions.

Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment.

Background: The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage due to adverse events (AEs).

Methods: We performed a retrospective cohort study of 98 patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who received 80 mg osimertinib as the initial treatment.